FV-162

• Description:

  FV-162 is a potent, orally active and irreversible proteasome inhibitor. FV-162 exhibits cytotoxic to human myeloma cell lines and primary myeloma cells. FV-162 inhibits tumor growth in a myeloma xenograft mouse model. FV-162 can be used for myeloma research[1].

• UNSPSC:

  12352005

• Target:

  Proteasome

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Cancer

• Smiles:

  O=C (C1=CN=C (C) S1) N[C@@H] (COC (F) F) C (N[C@@H] (COC (F) F) C (N[C@@H] (CC2=CC=CC=C2) C ([C@]3 (CO3) C) =O) =O) =O

• Molecular Formula:

  C25H28F4N4O7S

• Molecular Weight:

  604.57

• References & Citations:

  [1]Wang Z, et al. FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing. Cell Death Dis. 2015 Jul 9;6 (7) :e1815.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1565822-28-7